Relmada Therapeutics (RLMD) Competitors $0.60 -0.02 (-2.45%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. ENTX, ADAG, IVVD, SKYE, VNRX, ORMP, CHRS, IOBT, SRZN, and MGNXShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include Entera Bio (ENTX), Adagene (ADAG), Invivyd (IVVD), Skye Bioscience (SKYE), VolitionRx (VNRX), Oramed Pharmaceuticals (ORMP), Coherus Oncology (CHRS), IO Biotech (IOBT), Surrozen (SRZN), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors Entera Bio Adagene Invivyd Skye Bioscience VolitionRx Oramed Pharmaceuticals Coherus Oncology IO Biotech Surrozen MacroGenics Relmada Therapeutics (NASDAQ:RLMD) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Which has more risk & volatility, RLMD or ENTX? Relmada Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.46, indicating that its stock price is 46% more volatile than the S&P 500. Does the media favor RLMD or ENTX? In the previous week, Relmada Therapeutics had 4 more articles in the media than Entera Bio. MarketBeat recorded 5 mentions for Relmada Therapeutics and 1 mentions for Entera Bio. Entera Bio's average media sentiment score of 1.87 beat Relmada Therapeutics' score of 0.47 indicating that Entera Bio is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Neutral Entera Bio Very Positive Which has better valuation & earnings, RLMD or ENTX? Entera Bio has higher revenue and earnings than Relmada Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.51-0.24Entera Bio$180K479.50-$9.54M-$0.26-7.30 Is RLMD or ENTX more profitable? Relmada Therapeutics has a net margin of 0.00% compared to Entera Bio's net margin of -4,525.11%. Entera Bio's return on equity of -95.10% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -181.26% -151.23% Entera Bio -4,525.11%-95.10%-82.77% Do analysts recommend RLMD or ENTX? Relmada Therapeutics presently has a consensus target price of $5.00, indicating a potential upside of 730.56%. Entera Bio has a consensus target price of $10.00, indicating a potential upside of 426.59%. Given Relmada Therapeutics' higher probable upside, analysts plainly believe Relmada Therapeutics is more favorable than Entera Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Entera Bio 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in RLMD or ENTX? 45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 14.1% of Entera Bio shares are owned by institutional investors. 20.7% of Relmada Therapeutics shares are owned by company insiders. Comparatively, 10.4% of Entera Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryEntera Bio beats Relmada Therapeutics on 8 of the 14 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.98M$2.42B$5.50B$8.93BDividend YieldN/A1.79%5.38%4.12%P/E Ratio-0.248.9426.2519.86Price / SalesN/A665.31415.14113.78Price / CashN/A154.3736.4957.06Price / Book0.514.548.055.38Net Income-$79.98M$31.16M$3.16B$248.50M7 Day Performance11.48%0.15%1.78%2.78%1 Month Performance-15.03%8.74%4.74%5.84%1 Year Performance-79.87%2.17%35.81%20.06% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics4.784 of 5 stars$0.60-2.3%$5.00+730.6%-79.9%$19.98MN/A-0.2410News CoverageENTXEntera Bio2.8049 of 5 stars$1.97-0.8%$10.00+408.9%+5.7%$90M$180K-7.5620Positive NewsADAGAdagene1.985 of 5 stars$1.91+0.3%$8.00+319.9%-39.1%$89.51M$100K0.00260News CoverageIVVDInvivyd3.3673 of 5 stars$0.70-6.0%$5.85+734.3%-39.9%$89.48M$25.38M-0.58100News CoverageGap UpSKYESkye Bioscience2.1715 of 5 stars$2.87+32.9%$16.60+478.4%-53.6%$88.91MN/A-3.5011High Trading VolumeVNRXVolitionRx1.6391 of 5 stars$0.86-6.5%$3.50+306.9%+23.9%$88.61M$1.31M-2.3980Gap DownHigh Trading VolumeORMPOramed Pharmaceuticals0.5728 of 5 stars$2.11-0.9%N/A-18.0%$87.01M$1.34M-4.8010Gap UpCHRSCoherus Oncology4.1908 of 5 stars$0.73-2.7%$4.68+544.5%-52.8%$86.62M$266.96M-0.64330Positive NewsIOBTIO Biotech3.234 of 5 stars$1.30flat$9.33+617.9%+23.2%$85.64MN/A-0.9530Gap UpSRZNSurrozen2.9623 of 5 stars$9.02-9.7%$38.50+326.8%-17.7%$85.54M$10.65M-0.3680News CoverageMGNXMacroGenics4.1192 of 5 stars$1.32+0.8%$5.71+332.9%-70.7%$82.65M$149.96M-1.48430 Related Companies and Tools Related Companies Entera Bio Alternatives Adagene Alternatives Invivyd Alternatives Skye Bioscience Alternatives VolitionRx Alternatives Oramed Pharmaceuticals Alternatives Coherus Oncology Alternatives IO Biotech Alternatives Surrozen Alternatives MacroGenics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts